- Moderna, Inc. is a leading biotechnology company specializing in mRNA technology for vaccines and therapeutics, with a focus on infectious diseases, cancer, and rare diseases, headquartered in Cambridge, Massachusetts.
- In the past year, Moderna has launched its third product, reduced annual operating expenses by approximately $2 billion, and expects potential first approvals for its influenza vaccine and flu/COVID combination products in 2026.
- The company is actively presenting data at major conferences, including the 2026 ASCO Annual Meeting and ESCMID 2026, showcasing its investigational mRNA therapeutics and vaccines, which may attract partnerships with healthcare providers and research institutions.
- Moderna's ideal buyers include healthcare providers and government agencies looking to enhance vaccination programs, as they address the critical need for innovative mRNA vaccines to combat seasonal influenza and respiratory viruses.
Moderna's workforce is organized across 18 departments, with a significant concentration in Operations, which employs 645 individuals. Information Technology follows closely with 532 employees, reflecting the company's commitment to technological advancement. Engineering also plays a critical role, housing 320 staff members. The balance among these departments indicates a strong focus on operational efficiency and innovation, supported by a diverse range of other functional areas.
The company's workforce is predominantly located in Cambridge, MA, which accounts for 1,046 employees, making it the largest site. Boston and Norwood follow, with 126 and 97 employees, respectively. The presence of 2,021 employees in the 'Other' category suggests a distributed workforce across various locations, indicating flexibility in operations and potential remote work arrangements. This geographic distribution highlights a concentrated presence in Massachusetts while maintaining a broader reach.
